Divestment
Ventaleon
Ventaleon developed inhaled raloxifene and other therapies targeting severe viral lung infections and respiratory diseases.
Key Facts
- Sector
Life Sciences
- Country
Germany
- Fund
LSP 4
- Entry
2012
- Exit
2020
News
Do You Want to Know More?
We are eager to explore how we can achieve great things together.